COVID-19 Vaccine Booster Trial Blinded Elixir from Japan
Blinded liquid elixir placebo for oral intake in Phase IV COVID-19 booster trials, in 10ml sachets mimicking vaccine adjuvant taste profile. Falls under HTS 3006.93.60.00 as double-blinded clinical trial material in measured oral doses.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Provide emergency use authorization or IND linked to public health emergency trials for expedited clearance
• Label with trial phase and sponsor to distinguish from waste pharmaceuticals under 3006(k)
• Test for alcohol content if any, to avoid Chapter 22 reclassification